Positive allosteric modulation of α4β2 nicotinic receptors potentiates some CNS effects of the α4β2 agonist, ABT-594

被引：0
|
作者：
Franklin, S. R. [1 ]
Mohler, E. G. [1 ]
Komater, V. A. [1 ]
Robb, H. [1 ]
Radek, R. J. [1 ]
Rustay, N. R. [1 ]
Brown, J. W. [1 ]
Gopalakrishnan, M. [1 ]
Decker, M. W. [1 ]
Rueter, L. E. [1 ]
机构：
[1] Abbott Labs, Global Pharmaceut Res & Dev, Neurosci Res, Abbott Pk, IL 60064 USA
来源：
BIOCHEMICAL PHARMACOLOGY | 2009年 / 78卷 / 07期
关键词：
D O I：
10.1016/j.bcp.2009.06.083
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：921 / 921
页数：1
相关论文
共 50 条
  • [21] Structural characterization and agonist binding to human α4β2 nicotinic receptors
    daCosta, Corrie J. B.
    Sturgeon, R. Michel
    Hamouda, Ayman K.
    Blanton, Michael P.
    Baenziger, John E.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 407 (03) : 456 - 460
  • [22] Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors
    Mihalak, Karla B.
    Carroll, F. Ivy
    Luetje, Charles W.
    MOLECULAR PHARMACOLOGY, 2006, 70 (03) : 801 - 805
  • [23] Desformylflustrabromine, a positive allosteric modulator of α4β2-containing nicotinic acetylcholine receptors, enhances cognition in rats
    Nikiforuk, Agnieszka
    Litwa, Ewa
    Krawczyk, Martyna
    Popik, Piotr
    Arias, Hugo
    PHARMACOLOGICAL REPORTS, 2020, 72 (03) : 589 - 599
  • [24] Desformylflustrabromine, a positive allosteric modulator of α4β2-containing nicotinic acetylcholine receptors, enhances cognition in rats
    Agnieszka Nikiforuk
    Ewa Litwa
    Martyna Krawczyk
    Piotr Popik
    Hugo Arias
    Pharmacological Reports, 2020, 72 : 589 - 599
  • [25] Negative Allosteric Modulators That Target Human α4β2 Neuronal Nicotinic Receptors
    Henderson, Brandon J.
    Pavlovicz, Ryan E.
    Allen, Jerad D.
    Gonzalez-Cestari, Tatiana F.
    Orac, Crina M.
    Bonnell, Andrew B.
    Zhu, Michael X.
    Boyd, R. Thomas
    Li, Chenglong
    Bergmeier, Stephen C.
    Mckay, Dennis B.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 334 (03): : 761 - 774
  • [26] Unravelling the mechanism of action of NS9283, a positive allosteric modulator of (α4)3(β2)2 nicotinic ACh receptors
    Grupe, M.
    Jensen, A. A.
    Ahring, P. K.
    Christensen, J. K.
    Grunnet, M.
    BRITISH JOURNAL OF PHARMACOLOGY, 2013, 168 (08) : 2000 - 2010
  • [27] Deconstruction of the α4β2 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator Desformylflustrabromine
    German, Nadezhda
    Kim, Jin-Sung
    Jain, Atul
    Dukat, Malgorzata
    Pandya, Anshul
    Ma, Yilong
    Weltzin, Maegan
    Schulte, Marvin K.
    Glennon, Richard A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (20) : 7259 - 7267
  • [28] Identification of a Negative Allosteric Site on Human α4β2 and α3β4 Neuronal Nicotinic Acetylcholine Receptors
    Pavlovicz, Ryan E.
    Henderson, Brandon J.
    Bonnell, Andrew B.
    Boyd, R. Thomas
    McKay, Dennis B.
    Li, Chenglong
    PLOS ONE, 2011, 6 (09):
  • [29] ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]:: A novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors:: I.: In vitro characterization
    Donnelly-Roberts, DL
    Puttfarcken, PS
    Kuntzweiler, TA
    Briggs, CA
    Anderson, DJ
    Campbell, JE
    Piattoni-Kaplan, M
    McKenna, DG
    Wasicak, JT
    Holladay, MW
    Williams, M
    Arneric, SP
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1998, 285 (02): : 777 - 786
  • [30] Positive Allosteric Modulation of mGlu4 Receptors: Challenges and Opportunities
    Dale, E.
    Hong, H.
    Huang, X.
    Boyle, N. J.
    Collins, M. D.
    Tamm, J. A.
    Brodbeck, R. M.
    Zhong, H.
    Acher, F.
    Doller, D.
    CURRENT NEUROPHARMACOLOGY, 2014, 12 : 13 - 13
12345